Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause (NCT06806345) | Clinical Trial Compass
RecruitingPhase 1/2
Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
Egypt40 participantsStarted 2025-01-28
Plain-language summary
Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction would offer therapists the chance to undertake clinical decisions and consequently improve treatment efficiency.
Objectives: This Predictive validity, diagnostic study conduct to examine the effect of hyperbaric oxygen therapy on insulin resistance in postmenopausal women.
Who can participate
Age range
55 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* A)Inclusion Criteria
* All females were clinically diagnosed with Postmenopausal Insulin resistance.
* Their ages were ranged from 55-65 years old.
* Their BMI was 30-34.9 kg/m².
* All patients should had controlled blood glucose levels by oral hypoglycemic drugs.
* All patients should had cardiac Ejection Fraction \>or =50%.
* Their Chest X-ray reported normal.
* Their Ear ,nose , thorax will be clinically evaluated by a specialized ENT physician to ensure fitting for hyperbaric chamber
* Voluntary acceptance of participation in the study .
B)Exclusion Criteria:
Participants will be excluded if they have :
* Chronic obstructive pulmonary disease.
* Cardiac pacemakers.
* Epileptic fits.
* Physically disable .
* Any disorder that lead to ulcers other than diabetes such as ahistory of chronic peripheral arterial disease.
Exclusion Criteria:
\-
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
HgA1c
Timeframe: two months
2
Function
Timeframe: two months
3
fasting blood glucose level
Timeframe: every 10 sessions for 2months
Trial details
NCT IDNCT06806345
SponsorCairo University
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2025-03-28
Contact for this trial
Siham mohamed fahmy Head of Hyperbaric oxygen therapy unit, Assistant professor